Fixx Pharmaceuticals, Inc is a new biotechnology company in Las Vegas. Fixx Pharmaceuticals is focused on developing therapies specifically targeted to treat patients suffering from bleeding disorders with the use of CRISPR gene editing.
One of Fixx’s main areas of focus is Hemophilia. Hemophilia is an inherited bleeding disorder in which the blood does not clot properly. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally.
Jesse John Francis Clark, founder of Fixx Pharmaceuticals, is an internationally known professional, entrepreneur and passionate advocate for people living with Hemophilia and related bleeding disorders. Born with severe Hemophilia, Clark founded Hemo Times, an online breaking bleeding disorder news website in 2019.
Fixx Pharmaceuticals hopes to have the first gene-editing product available for Hemophilia patients in record time.
